Gilead Sciences, Inc. (NASDAQ:GILD) Insider Merdad Parsey Sells 164,211 Shares

Gilead Sciences, Inc. (NASDAQ:GILD) insider Merdad Parsey sold 164,211 shares of the business’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the sale, the insider now directly owns 80,801 shares of the company’s stock, valued at approximately $7,427,227.92. This trade represents a 67.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Merdad Parsey also recently made the following trade(s):

• On Wednesday, November 6th, Merdad Parsey sold 25,590 shares of Gilead Sciences stock. The shares were sold at an average price of $91.50, for a total value of $2,341,485.00.
• On Tuesday, October 1st, Merdad Parsey sold 2,000 shares of Gilead Sciences stock. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00.

Gilead Sciences Trading Up 0.2 %

NASDAQ:GILD traded up $0.17 on Friday, reaching $92.58. 3,850,965 shares of the company’s stock were exchanged, compared to its average volume of 7,064,693. The business has a fifty day moving average of $88.26 and a 200-day moving average of $77.69. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $98.90. The firm has a market capitalization of $115.38 billion, a price-to-earnings ratio of 1,028.67, a price-to-earnings-growth ratio of 2.87 and a beta of 0.17.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. The business had revenue of $7.55 billion for the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business’s revenue was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.29 earnings per share. As a group, analysts expect that Gilead Sciences, Inc. will post 4.37 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 30th. Investors of record on Friday, December 13th will be given a $0.77 dividend. The ex-dividend date is Friday, December 13th. This represents a $3.08 annualized dividend and a yield of 3.33%. Gilead Sciences’s dividend payout ratio (DPR) is 3,422.22%.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. State Street Corp raised its stake in shares of Gilead Sciences by 1.4% during the third quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company’s stock worth $5,044,795,000 after purchasing an additional 841,776 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of Gilead Sciences by 50.9% in the 3rd quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock worth $2,900,921,000 after acquiring an additional 11,665,593 shares during the period. FMR LLC boosted its holdings in shares of Gilead Sciences by 79.4% in the third quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock valued at $2,780,329,000 after acquiring an additional 14,680,161 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Gilead Sciences by 2.1% during the third quarter. Geode Capital Management LLC now owns 27,540,870 shares of the biopharmaceutical company’s stock worth $2,302,119,000 after acquiring an additional 574,421 shares during the period. Finally, Legal & General Group Plc lifted its position in Gilead Sciences by 0.8% in the second quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock valued at $851,743,000 after purchasing an additional 93,068 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Evercore ISI upgraded Gilead Sciences to a “strong-buy” rating in a report on Friday, August 9th. UBS Group raised their target price on shares of Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a report on Thursday, November 21st. Daiwa America upgraded Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. JPMorgan Chase & Co. raised their target price on Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Finally, Truist Financial boosted their target price on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research note on Friday, November 8th. Twelve research analysts have rated the stock with a hold rating, eleven have issued a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $95.41.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.